Literature DB >> 12743701

Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.

S S Soedamah-Muthu1, Y-F Chang, J Otvos, R W Evans, T J Orchard.   

Abstract

AIM/HYPOTHESIS: To examine whether nuclear magnetic resonance lipoprotein spectroscopy improves the prediction of coronary artery disease in patients with Type 1 diabetes, independently of conventional lipid and other risk factors.
METHODS: A prospective nested case-control design of subjects with childhood onset Type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study was used. 59 controls were age-, sex- and duration-matched to 59 incident cases of coronary artery disease (fatal or non-fatal myocardial infarction, angina, coronary stenosis >50%) occurring during 10 years of follow-up. Lipid mass and particle concentrations of VLDL, LDL, and HDL subclasses, grouped into three size categories (large, medium, and small), were assessed prior to event with nuclear magnetic resonance spectroscopy.
RESULTS: Univariate analyses showed that both lipid mass and particle concentrations of all three VLDL subclasses, small LDL, medium LDL, and medium HDL were increased in CAD cases compared to controls, while large HDL was decreased. Mean LDL and HDL particle sizes were lower in cases. In multivariate models using conventional lipid and non-lipid risk factors, triglycerides and overt nephropathy were the strongest predictors of CAD. Nuclear magnetic resonance measures further improved the prediction, i.e. large HDL particle concentration (OR=0.43, p=0.030), medium HDL mass (OR=3.79, p=0.026) and total VLDL particle concentration (OR=2.33, p=0.033). CONCLUSION/
INTERPRETATION: While these results underscore the importance of triglycerides and overt nephropathy in CAD risk in Type 1 diabetic patients, they also suggest that nuclear magnetic resonance lipoprotein spectroscopy could further refine its prediction and show novel findings concerning HDL subclasses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743701     DOI: 10.1007/s00125-003-1094-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  48 in total

1.  Subclasses of LpA-I in coronary artery disease: distribution and cholesterol efflux ability.

Authors:  C Decossin; G Castro; B Derudas; M Bertrand; J C Fruchart; C Fiévet
Journal:  Eur J Clin Invest       Date:  1997-04       Impact factor: 4.686

2.  Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins.

Authors:  S C Rumsey; N F Galeano; Y Arad; R J Deckelbaum
Journal:  J Lipid Res       Date:  1992-10       Impact factor: 5.922

3.  Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy.

Authors:  J D Otvos; E J Jeyarajah; D W Bennett
Journal:  Clin Chem       Date:  1991-03       Impact factor: 8.327

4.  A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

Authors:  G R Warnick; J J Albers
Journal:  J Lipid Res       Date:  1978-01       Impact factor: 5.922

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Quantitative determination of serum triglycerides by the use of enzymes.

Authors:  G Bucolo; H David
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

Review 7.  Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease.

Authors:  H B Brewer
Journal:  Am J Cardiol       Date:  1999-05-13       Impact factor: 2.778

8.  Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion.

Authors:  S G Mendoza; A Zerpa; H Carrasco; O Colmenares; A Rangel; P S Gartside; M L Kashyap
Journal:  Artery       Date:  1983

9.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

10.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

View more
  28 in total

1.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.

Authors:  Barry I Freedman; Carl D Langefeld; Mariana Murea; Lijun Ma; James D Otvos; Jolyn Turner; Peter A Antinozzi; Jasmin Divers; Pamela J Hicks; Donald W Bowden; Michael V Rocco; John S Parks
Journal:  Nephrol Dial Transplant       Date:  2011-09-19       Impact factor: 5.992

2.  Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum.

Authors:  Ville-Petteri Mäkinen; Pasi Soininen; Carol Forsblom; Maija Parkkonen; Petri Ingman; Kimmo Kaski; Per-Henrik Groop; Mika Ala-Korpela
Journal:  MAGMA       Date:  2006-12-15       Impact factor: 2.310

Review 3.  Cardiovascular risk assessment in type 2 diabetes mellitus.

Authors:  Ebaa Al-Ozairi; R Jan-Willem Middelbeek; Edward S Horton
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

4.  The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  T Costacou; J C Zgibor; R W Evans; J Otvos; M F Lopes-Virella; R P Tracy; T J Orchard
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

5.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome.

Authors:  Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas
Journal:  Atherosclerosis       Date:  2006-10-02       Impact factor: 5.162

6.  High-density lipoprotein cholesterol in diabetes: is higher always better?

Authors:  Tina Costacou; Rhobert W Evans; Trevor J Orchard
Journal:  J Clin Lipidol       Date:  2011-06-28       Impact factor: 4.766

7.  LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients.

Authors:  Rodney G Bowden; Ronald L Wilson; A Alexander Beaujean
Journal:  J Nephrol       Date:  2011 Nov-Dec       Impact factor: 3.902

8.  Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.

Authors:  Ying Zhang; Alicia J Jenkins; Arpita Basu; Julie A Stoner; Maria F Lopes-Virella; Richard L Klein; Timothy J Lyons
Journal:  J Lipid Res       Date:  2015-12-09       Impact factor: 5.922

9.  Lipoprotein particle concentrations in children and adults following Kawasaki disease.

Authors:  Jonathan Lin; Sonia Jain; Xiaoying Sun; Victoria Liu; Yuichiro Z Sato; Susan Jimenez-Fernandez; Ron S Newfield; Ray Pourfarzib; Adriana H Tremoulet; John B Gordon; Lori B Daniels; Jane C Burns
Journal:  J Pediatr       Date:  2014-07-16       Impact factor: 4.406

10.  The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Dhananjay Vaidya; Adrian Dobs; Susan M Gapstur; Sherita Hill Golden; Arlene Hankinson; Kiang Liu; Pamela Ouyang
Journal:  Metabolism       Date:  2008-06       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.